Compare Stocks

→ Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATX Costa		$2,934.88	$0.00 ▼ $0.00	N/A	N/A	N/A	N/A
FTT Federated Enhanced Treasury Income Fund		$0.00	$12.81 ▼ $13.82	N/A	N/A	24,050 shs	N/A
MTFB MOTIF BIO PLC/S	$0.11	$0.10	$0.08 ▼ $11.50	N/A	N/A	N/A	867,698 shs
RVV Revive Therapeutics	C$0.08 +14.3%	C$0.08	C$0.07 ▼ C$0.25	C$5.79M	N/A	93,085 shs	212,852 shs

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATX Costa	0.00%	0.00%	0.00%	0.00%	0.00%
MTFB MOTIF BIO PLC/S	0.00%	0.00%	0.00%	0.00%	0.00%
RVV Revive Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%

These AI trades triggered this morning (545% return) (Ad)

If you think a market crash is possible in 2024, I don't know why you're not using this yet.

Click Here To Get Your Free Copy

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATX Costa	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FTT Federated Enhanced Treasury Income Fund	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MTFB MOTIF BIO PLC/S	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RVV Revive Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATX Costa	N/A	N/A	N/A	N/A
FTT Federated Enhanced Treasury Income Fund	3.00	Buy	$50.00	∞ Upside
MTFB MOTIF BIO PLC/S	N/A	N/A	N/A	N/A
RVV Revive Therapeutics	N/A	N/A	N/A	N/A

Current Analyst Ratings

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATX Costa	N/A	N/A	N/A	N/A	N/A	N/A
FTT Federated Enhanced Treasury Income Fund	N/A	N/A	N/A	N/A	N/A	N/A
MTFB MOTIF BIO PLC/S	N/A	N/A	N/A	N/A	N/A	N/A
RVV Revive Therapeutics	N/A	N/A	C$0.03 per share	3.18	C$0.02 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATX Costa	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
FTT Federated Enhanced Treasury Income Fund	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
MTFB MOTIF BIO PLC/S	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
RVV Revive Therapeutics	N/A	-C$0.02	N/A	∞	N/A	N/A	N/A	N/A	6/4/2024 (Estimated)

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATX Costa	N/A	N/A	N/A	N/A	N/A
FTT Federated Enhanced Treasury Income Fund	N/A	N/A	N/A	N/A	N/A
MTFB MOTIF BIO PLC/S	N/A	N/A	N/A	N/A	N/A
RVV Revive Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATX Costa	N/A	N/A	N/A
FTT Federated Enhanced Treasury Income Fund	N/A	N/A	N/A
MTFB MOTIF BIO PLC/S	N/A	N/A	N/A
RVV Revive Therapeutics	N/A	6.14	6.03

Ownership

Institutional Ownership

Company	Institutional Ownership
ATX Costa	N/A
FTT Federated Enhanced Treasury Income Fund	N/A
MTFB MOTIF BIO PLC/S	N/A
RVV Revive Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
ATX Costa	N/A
FTT Federated Enhanced Treasury Income Fund	N/A
MTFB MOTIF BIO PLC/S	N/A
RVV Revive Therapeutics	N/A

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ATX Costa	N/A	N/A	N/A	Not Optionable
FTT Federated Enhanced Treasury Income Fund	N/A	N/A	N/A	Not Optionable
MTFB MOTIF BIO PLC/S	7	N/A	N/A	Not Optionable
RVV Revive Therapeutics	N/A	72.41 million	N/A	Not Optionable

MTFB, RVV, BPH, FTT, and ATX Headlines

Source	Headline
	Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID tmcnet.com - April 23 at 8:07 AM
	Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product markets.businessinsider.com - April 18 at 8:03 AM
	Revive Therapeutics Ltd.: Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID finanznachrichten.de - March 27 at 4:23 PM
	Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID finance.yahoo.com - March 27 at 10:10 AM
	Revive Therapeutics Ltd.: Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID finanznachrichten.de - March 19 at 11:42 AM
	Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID markets.businessinsider.com - March 19 at 11:42 AM
	Revive Therapeutics Ltd.: Revive Therapeutics Provides Corporate Update finanznachrichten.de - March 12 at 8:23 AM
	Revive Therapeutics Provides Corporate Update financialpost.com - March 12 at 7:08 AM
	Revive Therapeutics Ltd. Announces Closing of the Second and Final Tranche of Its Private Placement for Gross Proceeds of $1,187,110 markets.businessinsider.com - February 26 at 8:53 PM
	Revive Therapeutics Explores the Use of Bucillamine for Long COVID markets.businessinsider.com - February 1 at 9:20 AM
	Revive Therapeutics Ltd. Announces Closing of the First Tranche of Its Private Placement for Gross Proceeds of $913,500 markets.businessinsider.com - January 31 at 7:29 PM
	Revive Therapeutics Ltd. Announces Offering of Up to $3 Million financialpost.com - January 24 at 7:03 PM
	Revive Therapeutics Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development Canada tmcnet.com - January 16 at 8:29 AM
	Revive Therapeutics Ltd.: Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of Bucillamine finanznachrichten.de - January 10 at 2:05 PM
	Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of Bucillamine markets.businessinsider.com - January 10 at 9:05 AM
	Travere Therapeutics expects Q4 net product sales from continuing operations to be about $40M msn.com - January 8 at 4:03 PM
	Revive Therapeutics Announces Results of Annual General and Special Meeting of Shareholders markets.businessinsider.com - December 20 at 5:50 PM
	Revive Therapeutics To Work With Attwill For Development Of Lyophilized Formulation Of Bucillamine markets.businessinsider.com - December 18 at 8:03 AM
	Revive Therapeutics Collaborates with Attwill Medical Solutions for the Clinical and Commercial Development of a Novel Lyophilized Formulation of Bucillamine financialpost.com - December 18 at 7:07 AM
	Revive Therapeutics Enters into Agreement with Defence Research and Development Canada for Evaluating Bucillamine for Nerve Agent Exposure markets.businessinsider.com - October 17 at 4:48 PM
	Revive Therapeutics Agrees With DRDC To Evaluate Bucillamine For Nerve Agent Exposure markets.businessinsider.com - October 17 at 11:47 AM
	Revive Therapeutics Ltd.: Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development finanznachrichten.de - October 11 at 2:48 PM
	Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development tmcnet.com - October 11 at 9:47 AM
	Revive I-5 project continues with driving surface improvement work starting Monday komonews.com - October 11 at 12:00 AM

Media Sentiment Over Time

Company Descriptions

Costa

NASDAQ:ATX

Costa Inc, formerly A. T. Cross Company is a designer and marketer of branded personal accessories, including writing instruments, reading glasses, personal and business accessories and sunglasses. The Company's Cross Optical Group (COG) consists of its wholly owned subsidiary, Cross Optical Group, Inc. and is the legal entity of the Company's two sunglass brands: Costa and Native. The Company's COG designs, manufactures and markets polarized sunglasses under the brand names Costa and Native. The Company's brands offer sunglasses in more than 75 styles and 25 lens options. In September 2013, the Company sold its Cross Accessory Division and the rights to the A.T. Cross name, which was associated with the writing instrument business. Effective February 3, 2014, Essilor International SA acquired Costa Inc.

Federated Enhanced Treasury Income Fund

NYSE:FTT

Federated Premier Intermediate Municipal Income Fund (the Fund) is a diversified, closed-end management investment company. The Fund's investment objective is to provide current income exempt from federal income tax, including the federal alternative minimum tax (AMT). The Fund's portfolio of investments include various sectors namely transportation, special tax, hospital, education, public power, senior care, water and sewer, general obligation-local, industrial development bond/pollution control revenue and general obligation-state. The Fund invests in intermediate-term, tax-exempt municipal bonds diversified among states, sectors and issuers. Federated Investment Management Company is the advisor of the Fund.

MOTIF BIO PLC/S

NASDAQ:MTFB

Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis. Motif Bio plc was incorporated in 2014 and is based in New York, New York.

Revive Therapeutics

CVE:RVV

Revive Therapeutics Ltd. develops and commercializes cannabinoid-based products in Canada. The company develops REV-002, a bucillamine that has completed Phase II-A clinical studies for the treatment of acute gout flares. Its product pipeline also includes REV-004, a bucillamine for the treatment of cystinurial. The company has a research and development supply and collaboration agreement with WeedMD Inc. Revive Therapeutics Ltd. was incorporated in 2012 and is headquartered in Vaughan, Canada.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial